OpenURL Connection Search

Select item for more details and to access through your institution.

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
Published in:
Arthritis Research & Therapy, 2024, v. 26, n. 1, p. 1, doi. 10.1186/s13075-024-03358-x
By:
- van Vollenhoven, Ronald;
- Strand, Vibeke;
- Takeuchi, Tsutomu;
- Chávez, Nilmo;
- Walter, Pablo Mannucci;
- Singhal, Atul;
- Swierkot, Jerzy;
- Khan, Nasser;
- Bu, Xianwei;
- Li, Yihan;
- Penn, Sara K.;
- Camp, Heidi S.;
- Aelion, Jacob
Publication type:
Article
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Published in:
Arthritis Research & Therapy, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13075-023-03128-1
By:
- Baraliakos, Xenofon;
- van der Heijde, Désirée;
- Sieper, Joachim;
- Inman, Robert D.;
- Kameda, Hideto;
- Li, Yihan;
- Bu, Xianwei;
- Shmagel, Anna;
- Wung, Peter;
- Song, In-Ho;
- Deodhar, Atul
Publication type:
Article
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Published in:
Rheumatology & Therapy, 2021, v. 8, n. 2, p. 903, doi. 10.1007/s40744-021-00305-z
By:
- Mease, Philip J.;
- Lertratanakul, Apinya;
- Papp, Kim A.;
- van den Bosch, Filip E.;
- Tsuji, Shigeyoshi;
- Dokoupilova, Eva;
- Keiserman, Mauro W.;
- Bu, Xianwei;
- Chen, Liang;
- McCaskill, Reva M.;
- Zueger, Patrick;
- McDearmon-Blondell, Erin L.;
- Pangan, Aileen L.;
- Tillett, William
Publication type:
Article

Found: 3

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.